Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration

Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration

Authors

  • Piergiorgio Neri
  • Ilir Arapi
  • Chiara Maria Eandi
  • Vittorio Pirani
  • Cesare Mariotti
  • Alfonso Giovannini

DOI:

https://doi.org/10.7175/fe.v15i4.976

Keywords:

Age-Related Macular Degeneration, Anti-VEGF, Intravitreal injection

Abstract

Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies. Anti-VEGFs currently used to treat AMD included a monoclonal antibody (bevacizumab), an antibody fragments (ranibizumab), a fusion protein (aflibercept), and an aptamer (pegaptanib). The wide introduction of anti-VEGF therapy has led to an improvement in the prognosis of patients affected by AMD, with a consequent effects on the burden of care due to highly priced drugs, increasing patient numbers, and long-term disease chronicity. Aim of this review is to present an overview of available therapeutic strategies in AMD in term of clinical efficacy and economic sustainability.

References

Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31; http://dx.doi.org/10.1056/NEJMoa054481

Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432- 44; http://dx.doi.org/10.1056/NEJMoa062655

Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-48; http://dx.doi.org/10.1016/j.ajo.2007.10.004

Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-9; http://dx.doi.org/10.1016/j.ophtha.2009.05.024

Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58; http://dx.doi.org/10.1016/j.ajo.2009.01.024

CATT Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908; http://dx.doi.org/10.1056/NEJMoa1102673

Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258-67; http://dx.doi.org/10.1016/S0140-6736(13)61501-9

Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 2014; 252: 647-55; http://dx.doi.org/10.1007/s00417-013-2562-6

Sivaprasad S, Tadayoni R. Retrospective analysis of the real-world utilization of ranibizumab in wAMD. AURA Steering Committee. Presented at the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); Seattle, 2013. Abstract 3836

Rakic J-M, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013; 7: 1849-58; http://dx.doi.org/10.2147/OPTH.S49385

Heier JS, Brown DM, Chong V, et al.; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-48; http://dx.doi.org/10.1016/j.ophtha.2012.09.006

Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155: 429-37; http://dx.doi.org/10.1016/j.ajo.2012.09.026

Do DV, Nguyen QD, Boyer D, et al.; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-65; http://dx.doi.org/10.1016/j.ophtha.2012.02.010

Cho H, Shah CP, Weber M, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-5; http://dx.doi.org/10.1136/bjophthalmol-2013-303344

Bakall B, Folk JC, Boldt HC, et al. Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab. Am J Ophthalmol 2013; 156: 15-22; http://dx.doi.org/10.1016/j.ajo.2013.02.017

Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006; 37: 446-54

Friberg TR, Tolentino M, LEVEL Study Group, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010; 94: 1611-17; http://dx.doi.org/10.1136/bjo.2009.174946

Gragoudas ES, Adamis AP, Cunningham Jr ET, et al.; VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16; http://dx.doi.org/10.1056/NEJMoa042760

Mitchell P1, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011; 29: 107-31; http://dx.doi.org/10.2165/11585520-000000000-00000

Cicchetti A, Ruggeri M. Valutazione economica di ranibizumab vs pegaptanib o vs terapia fotodinamica con verteporfina. JPH 2009; 6(Suppl. 3): 31-44

Holz FG, Bandello F, Gillies M, et al.; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol 2013; 97: 1161-7; http://dx.doi.org/10.1136/bjophthalmol-2013-303232

Nishimura Y, Taguchi M, Nagai T, et al. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. Clin Ophthalmol 2012; 6: 365-8

Neri P, Mariotti C, Arapi I, et al. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal? Curr Med Res Opin 2012; 28: 395-400; http://dx.doi.org/10.1185/03007995.2012.662153

Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol 2013; 182: 1379-90; http://dx.doi.org/10.1016/j.ajpath.2012.12.032

Downloads

Published

2014-12-23

How to Cite

Neri, P., Arapi, I., Eandi, C. M., Pirani, V., Mariotti, C., & Giovannini, A. (2014). Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration. Farmeconomia. Health Economics and Therapeutic Pathways, 15(4), 129–138. https://doi.org/10.7175/fe.v15i4.976

Issue

Section

Review (Economic Analysis)

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.

Loading...